Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

1994, Randomised trial of cholesterol lowering in 444 patients with coronary heart disease, Lancet, 344, 1383 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 2002, The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 Kjekshus, 1997, The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease, J Card Fail, 3, 249, 10.1016/S1071-9164(97)90022-1 Aronow, 2002, Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid lowering drug, Am J Cardiol, 90, 147, 10.1016/S0002-9149(02)02438-4 Lefer, 2002, Statins as potent anti-inflammatory drugs, Circulation, 106, 2041, 10.1161/01.CIR.0000033635.42612.88 von Haehling, 2003, Statins and the role of nitric oxide in chronic heart failure, Heart Fail Rev, 8, 99, 10.1023/A:1022103222857 Rosenson, 1999, Inhibition of proinflammatory cytokine production by pravastatin, Lancet, 353, 983, 10.1016/S0140-6736(98)05917-0 Hayashidani, 2002, Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction, Circulation, 105, 868, 10.1161/hc0702.104164 Dechend, 2001, Amelioration of angiotensin II–induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, Circulation, 104, 576, 10.1161/hc3001.092039 Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003;107:2493–8 Maggioni, 2001, Debate, Curr Control Trials Cardiovasc Med, 2, 226 Krum, 2002, Statins and chronic heart failure, J Am Coll Cardiol, 39, 1567, 10.1016/S0735-1097(02)01827-2 Horwich, 2002, Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure, J Card Fail, 8, 216, 10.1054/jcaf.2002.0804216 Rauchhaus, 2000, Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure, Int J Cardiol, 76, 125, 10.1016/S0167-5273(00)00224-2 Ashton, 2003, Should patients with chronic heart failure be treated with ‘statins'?, Heart Fail Monit, 3, 82 Sueta, 2003, Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure, J Card Fail, 9, 36, 10.1054/jcaf.2003.5 Uretsky, 2000, Acute coronary findings at autopsy in heart failure patients with sudden death, Circulation, 102, 611, 10.1161/01.CIR.102.6.611 Fonarow, 1997, Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure, J Am Coll Cardiol, 30, 725, 10.1016/S0735-1097(97)00208-8 Aaronson, 1999, Mortality remains high for outpatient transplant candidates with prolonged (>6 months) waiting list time, J Am Coll Cardiol, 33, 1189, 10.1016/S0735-1097(98)00697-4 Remme, 2000, Overview of the relationship between ischemia and congestive heart failure, Clin Cardiol, 23, IV4 Rosenson, 1998, Antiatherothrombotic properties of statins, JAMA, 279, 1643, 10.1001/jama.279.20.1643 Vaughan, 1996, Statins do more than just lower cholesterol, Lancet, 348, 1079, 10.1016/S0140-6736(96)05190-2 Kureishi, 2000, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Aktand promotes angiogenesis in normocholesterolemic animals, Nat Med, 6, 1004, 10.1038/79510 Bauersachs, 2001, Improvement of left ventricular remodeling and function by hyroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure, Circulation, 104, 982, 10.1161/hc3401.095946 Indolfi, 2002, Hydroxymethylgluatryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21rasactivation, Circulation, 106, 2118, 10.1161/01.CIR.0000034047.70205.97 Deswal, 2001, Cytokines and cytokine receptors in advanced heart failure, Circulation, 103, 2055, 10.1161/01.CIR.103.16.2055 Rauchhaus, 2000, Plasma cytokine parameters and mortality in patients with chronic heart failure, Circulation, 102, 3060, 10.1161/01.CIR.102.25.3060 Feldman, 2000, The role of tumor necrosis factor in the pathophysiology of heart failure, J Am Coll Cardiol, 35, 537, 10.1016/S0735-1097(99)00600-2 Ridker, 1999, Long-term effects of pravastatin and plasma concentration of C-reactive protein, Circulation, 100, 230, 10.1161/01.CIR.100.3.230 Katz, 1999, Decreased activity of l-arginine–nitric oxide metabolic pathway in patients with congestive heart failure, Circulation, 99, 2113, 10.1161/01.CIR.99.16.2113 Jones, 2003, Endothelial nitric oxide synthase overexpression in mice attenuates congestive heart failure in mice, Proc Natl Acad Sci USA, 100, 4891, 10.1073/pnas.0837428100 Cohn, 1993, Mechanistic data from the VA Cooperative studies, Circulation, 86, VI-5 Pliquett RU, Cornish KG, Zudker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003;95:700–4